UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

Published on September 10, 2012 at 12:30 AM · 5 Comments

Efforts to begin human clinical trials using stem cells to treat Alzheimer's disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Sept. 5.

UC Irvine scientists will be part of two research teams garnering CIRM Disease Team Therapy Development Awards, which are designed to accelerate collaborative translational research leading to human clinical trials. In one, Dr. Henry Klassen, an associate professor of ophthalmology in UC Irvine's Sue & Bill Gross Stem Cell Research Center, and his collaborators at UC Santa Barbara and Cedars-Sinai Medical Center, received $17.3 million to cultivate therapeutically potent retinal progenitor stem cells to treat the blinding effects of retinitis pigmentosa.

In the other, StemCells, Inc. in Newark, Calif., received $20 million and will collaborate with Frank LaFerla and Mathew Blurton-Jones - neurobiologists with the stem cell research center and the Institute for Memory Impairments and Neurological Disorders (UCI MIND) - to advance research using the company's proprietary purified human neural stem cells to improve memory in people with Alzheimer's disease.

"CIRM's support for UC Irvine's efforts to advance stem cell-based treatments for a variety of diseases is extremely gratifying," said Peter Donovan, director of the Sue & Bill Gross Stem Cell Research Center. "Henry's work on retinitis pigmentosa and Frank and Mathew's on Alzheimer's disease hold great promise, and we are delighted that they have the support to see their work move toward the clinic."

Klassen's objective is to introduce stem cells that rescue and reactivate damaged and dying photoreceptor rods and cones, thus reversing the course of RP even at relatively advanced stages. The current CIRM funding will allow Klassen and his collaborators to grow these cells under conditions ensuring that pharmaceutical standards are met. The resulting cells will be tested in animals for safety and to make certain that they are therapeutically potent. Then the team will seek FDA approval for the use of these cells in early clinical trials, in which a small number of patients with severe RP will be injected with cells in their worse-seeing eye and followed clinically for a specified period of time to determine the safety and effectiveness of the treatment.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
  1. RP
    WANDA PARRIS WANDA PARRIS United States says:

    I have RP and would love to get in Clinical Trials. Can you tell me who to contact and where they will be. So excited someone could help us. Please answer and let me know..thanks

  2. CharlieMyBoy CharlieMyBoy United States says:

    I do, too. Although it's progressed pretty slowly since I was 21 (40 years ago), it certainly seems to have picked up speed in the last few years. The advancement is noticeable, and I'd love the opportunity to be a test subject, since I plan to be around another 30 years or so and would love to see my world during that time.

  3. jamie reynolds jamie reynolds Australia says:

    hi i am wondering who i would speak to about r/p trials find out my 2 good friends (brothers)have r/p and losing there sight quite fast they are down 2 about 20% its sad any possibility to give them any improvment would be amazing any info would be fantastic

  4. jamie reynolds jamie reynolds Australia says:

    we would be willing to move to america to do these trials

  5. S.M. Pande S.M. Pande India says:

    I am looking for treatment for PR. is it possible to get the treatment so that I will able to maintain my present sight.
    I have high miopia & Recently I got operated for catract.

    Today it is fine, but for future is there any option available.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment